Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

Inclusion Criteria: 1. biopsy-confirmed esophageal squamous cell carcinoma 2. age ≤ 70 years old, 3. Karnofsky performance status ≥ 70, 4. R0 esophagectomy according to the pathological examination of the resected specimens, 5. postoperative stage Ⅱ-Ⅳa according to the AJCC 7th edition of tumor-node-metastasis (TNM) classification for esophageal carcinoma 6. Adequate organ functions (1).white blood cell (WBC) ≥3×109⁄L; (2).Absolute neutrophil counts (ANC) ≥1.5×109⁄L; (3).Hemoglobin (Hb) ≥10g⁄dl; (4).Platelet (Plt) ≥100×109⁄L; (5).Total bilirubin \<1.5 upper limit of normal (ULN); (6).Aspartate transaminase (AST) ≤2.5 ULN; (7).Alanine aminotransferase (ALT) ≤2.5 ULN; (8).Creatinine ≤1.5 ULN; (9).adequate pulmonary function (FEV1\>0.8 L;. 7. no previous treatment or severe complications 8. Written informed consent Exclusion Criteria: 1. previous treatment with chemotherapy or radiotherapy 2. greater than 3 months after surgery 3. complete esophageal obstruction after surgery, esophageal perforation; 4. other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ, who survived with no evidence disease for over 3 years; 5. pregnant or breast-feeding women； 6. patients with any serious concurrent disease, such as severe diabetes, uncontrolled hypertension, serious chronic obstructive pulmonary disease； 7. drug addiction, Alcoholism or AIDS; 8. uncontrolled seizures or psychiatric diseases, loss of control over their own behavior; 9. with clear chemotherapy drug allergy 10. participation in other interventional clinical trials within 30 days;